Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genor Biopharma Holdings Limited ( (HK:6998) ) has provided an announcement.
Edding Genor Group Holdings has scheduled a board meeting for 27 March 2026 to review and approve the annual results for the year ended 31 December 2025 and to authorize their publication. The board will also consider whether to recommend a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also reconfirms the current composition of the board, listing the chairman, executive, non-executive and independent non-executive directors overseeing governance. This scheduled meeting marks a key point in the company’s financial reporting cycle and provides investors with a timeline for forthcoming earnings disclosure and potential dividend policy updates.
The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 6998. The group operates through a board structure comprising executive, non-executive and independent non-executive directors, reflecting a typical governance framework for mid-cap listed corporates in the region.
Average Trading Volume: 1,309,742
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.52B
Find detailed analytics on 6998 stock on TipRanks’ Stock Analysis page.